Pune, India -- (SBWIRE) -- 09/04/2019 -- Global Embolic Agents Market Overview:
The report spread across 90 pages is an overview of the Global Embolic Agents Market Report 2019. The Global Embolic Agents Market is projected to grow at a healthy growth rate from 2019 to 2023 according to new research. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies.
The Global Embolic Agents Market research report is the study prepared by analysts, which contain a detailed analysis of drivers, restraints, and opportunities along with their impact on the Embolic Agents Market growth (2019 - 2023).
Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/155423 .
The Global Embolic Agents Market is segmented on the basis of Type, Application and Region. Based on the Type, the Global Embolic Agents Market is classified into Liquid Embolic Agents, Particulate Embolic Agents and others. On the basis of Application, the Global Embolic Agents Market is sub-segmented into Occlude Bleeding, Oncotherapy, Malignant Hypertension and others.
In terms of the regional analysis, North America dominates the Global Embolic Agents Market due to advanced health care infrastructure, high health care spending, and presence of a large number of cancer patients in the region. Factors such as growing geriatric population and increasing number of surgical procedures make Europe the second-largest market for Embolic Agents. Embolic Agents Market in the APAC region is expected to expand at a higher rate during the forecast period, due to rising health care expenditure, favorable government initiatives, boom in the economy, developing health care infrastructure, rising prevalence of chronic diseases, growing awareness among people, and increasing R&D activities in the region.
Latest Business News:
Johnson & Johnson (April 14, 2019) – INVOKANA (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 CREDENCE study, showing that INVOKANA (canagliflozin) demonstrated a 30 percent reduction in the risk of the primary composite endpoint, comprised of progression to end-stage kidney disease (ESKD), defined as the need for renal replacement therapy (RRT) such as chronic dialysis or renal transplant; doubling of serum creatinine, a key predictor of ESKD; and renal or cardiovascular (CV) death. The landmark study evaluated the efficacy and safety of INVOKANA versus placebo in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) when used in addition to standard of care. Study results also showed INVOKANA reduced the risk of the secondary CV endpoints, including the risk of CV death and hospitalization for heart failure by 31 percent, major adverse CV events (MACE; composite of nonfatal myocardial infarction [MI], nonfatal stroke and CV death) by 20 percent, and the risk of hospitalization for heart failure alone by 39 percent. Importantly, the study showed no imbalance in amputation or bone fracture. Additionally, no new safety concerns were identified in this study of high-risk patients.
Top Leading Key Manufacturers in Global Embolic Agents Market: Medtronic, Terumo, Boston Scientific, Merit Medical, Johnson & Johnson, GEM Italy, IMBiotechnologies Ltd (IMB), Emboflu, BTG, Cook Medical and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.
With the presence of a large pool of participants, the Global Embolic Agents Market is displaying a highly competitive business landscape, finds a new research report by Business Industry Reports (BIR). Medtronic, Terumo, Boston Scientific, Merit Medical, Johnson & Johnson, GEM Italy, IMBiotechnologies Ltd (IMB), Emboflu, BTG, Cook Medical are some of the key vendors of Embolic Agents across the world. These players across Embolic Agents Market are focusing aggressively on innovation, as well as on including advanced technologies in their existing products.
Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Embolic Agents in these regions, from 2013 to 2023 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Global Embolic Agents Market Report 2019" @ https://www.businessindustryreports.com/buy-now/155423/single .
Major Points in Table of Contents:
Global Embolic Agents Market Report 2019
1 Embolic Agents Product Definition
2 Global Embolic Agents Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Embolic Agents Shipments
2.2 Global Manufacturer Embolic Agents Business Revenue
2.3 Global Embolic Agents Market Overview
3 Manufacturer Embolic Agents Business Introduction
3.1 Medtronic Embolic Agents Business Introduction
………………. Request free sample to get a complete Table of Content
About BusinessindustryReports.com
BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.
Media Contact
Business Industry Reports
Pune – India
sales@businessindustryreports.com
+19376349940